These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 14581345)

  • 21. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase.
    Parkhurst MR; Riley JP; Igarashi T; Li Y; Robbins PF; Rosenberg SA
    Clin Cancer Res; 2004 Jul; 10(14):4688-98. PubMed ID: 15269141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment of HLA-DR4 transgenic mice for the identification of CD4+ T cell epitopes of tumor-associated antigens.
    Yatsuda J; Irie A; Harada K; Michibata Y; Tsukamoto H; Senju S; Tomita Y; Yuno A; Hirayama M; Abu Sayem M; Takeda N; Shibuya I; Sogo S; Fujiki F; Sugiyama H; Eto M; Nishimura Y
    PLoS One; 2013; 8(12):e84908. PubMed ID: 24386437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE.
    Miyahara Y; Naota H; Wang L; Hiasa A; Goto M; Watanabe M; Kitano S; Okumura S; Takemitsu T; Yuta A; Majima Y; Lemonnier FA; Boon T; Shiku H
    Clin Cancer Res; 2005 Aug; 11(15):5581-9. PubMed ID: 16061876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes.
    Kobayashi H; Ngato T; Sato K; Aoki N; Kimura S; Tanaka Y; Aizawa H; Tateno M; Celis E
    Clin Cancer Res; 2006 Jun; 12(12):3814-22. PubMed ID: 16778109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
    Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
    Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope.
    Schreurs MW; Kueter EW; Scholten KB; Kramer D; Meijer CJ; Hooijberg E
    Cancer Immunol Immunother; 2005 Jul; 54(7):703-12. PubMed ID: 15726360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3.
    Consogno G; Manici S; Facchinetti V; Bachi A; Hammer J; Conti-Fine BM; Rugarli C; Traversari C; Protti MP
    Blood; 2003 Feb; 101(3):1038-44. PubMed ID: 12393675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response.
    Godet Y; Fabre E; Dosset M; Lamuraglia M; Levionnois E; Ravel P; Benhamouda N; Cazes A; Le Pimpec-Barthes F; Gaugler B; Langlade-Demoyen P; Pivot X; Saas P; Maillère B; Tartour E; Borg C; Adotévi O
    Clin Cancer Res; 2012 May; 18(10):2943-53. PubMed ID: 22407833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
    Kobayashi H; Song Y; Hoon DS; Appella E; Celis E
    Cancer Res; 2001 Jun; 61(12):4773-8. PubMed ID: 11406551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of CDCA1-derived long peptides bearing both CD4+ and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer patients.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Yoshimura S; Osawa R; Kuroda Y; Hirayama M; Irie A; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Int J Cancer; 2014 Jan; 134(2):352-66. PubMed ID: 24734272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor.
    Purbhoo MA; Li Y; Sutton DH; Brewer JE; Gostick E; Bossi G; Laugel B; Moysey R; Baston E; Liddy N; Cameron B; Bennett AD; Ashfield R; Milicic A; Price DA; Classon BJ; Sewell AK; Jakobsen BK
    Mol Cancer Ther; 2007 Jul; 6(7):2081-91. PubMed ID: 17620437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II molecules.
    Ribeiro SP; Rosa DS; Fonseca SG; Mairena EC; Postól E; Oliveira SC; Guilherme L; Kalil J; Cunha-Neto E
    PLoS One; 2010 Jun; 5(6):e11072. PubMed ID: 20552033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peptide immunisation of HLA-DR-transgenic mice permits the identification of a novel HLA-DRbeta1*0101- and HLA-DRbeta1*0401-restricted epitope from p53.
    Rojas JM; McArdle SE; Horton RB; Bell M; Mian S; Li G; Ali SA; Rees RC
    Cancer Immunol Immunother; 2005 Mar; 54(3):243-53. PubMed ID: 15449037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain.
    Voutsas IF; Gritzapis AD; Mahaira LG; Salagianni M; Hofe EV; Kallinteris NL; Baxevanis CN
    Int J Cancer; 2007 Nov; 121(9):2031-2041. PubMed ID: 17634957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1.
    Matsuzaki J; Qian F; Luescher I; Lele S; Ritter G; Shrikant PA; Gnjatic S; Old LJ; Odunsi K
    Cancer Immunol Immunother; 2008 Aug; 57(8):1185-95. PubMed ID: 18253733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
    Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R
    Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
    Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
    Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
    Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies.
    Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S
    Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.